Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Instil Bio, Inc.
  6. Summary
    TIL   US45783C1018

INSTIL BIO, INC.

(TIL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
21.98(c) 21.69(c) 21.88(c) 19.94(c) 19.81(c) Last
664 388 365 974 416 865 671 696 799 582 Volume
+0.83% -1.32% +0.88% -8.87% -0.65% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,03 M - -
Net income 2021 -149 M - -
Net cash position 2021 105 M - -
P/E ratio 2021 -14,0x
Yield 2021 -
Sales 2022 0,28 M - -
Net income 2022 -215 M - -
Net Debt 2022 154 M - -
P/E ratio 2022 -11,4x
Yield 2022 -
Capitalization 2 554 M 2 554 M -
EV / Sales 2021 70 994x
EV / Sales 2022 9 520x
Nbr of Employees 382
Free-Float 93,1%
More Financials
Company
Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. It is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. It is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory... 
More about the company
Ratings of Instil Bio, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about INSTIL BIO, INC.
11/15Instil Bio Posts Narrower Q3 Loss
MT
11/15INSTIL BIO : Announces Poster Presentations at the 2021 Society for Immunotherapy of Cance..
PU
11/15INSTIL BIO, INC. : Other Events (form 8-K)
AQ
11/15INSTIL BIO, INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
11/15INSTIL BIO : Reports Third Quarter 2021 Financial Results and Provides Corporate Update - ..
PU
11/15INSTIL BIO, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/15Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Canc..
AQ
11/15Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
AQ
11/08Instil Bio to Present at Upcoming Investor Conferences in November
AQ
09/20INSTIL BIO, INC.(NASDAQGS : TIL) added to S&P Global BMI Index
CI
09/16INSTIL BIO : Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Mela..
PU
09/16INSTIL BIO, INC. : Other Events (form 8-K)
AQ
09/16INSTIL BIO : Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Mela..
AQ
09/16Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Mel..
CI
09/15Certain Options of Instil Bio, Inc. are subject to a Lock-Up Agreement Ending on 15-SEP..
CI
More news
News in other languages on INSTIL BIO, INC.
11/15Instil Bio affiche une perte plus étroite au troisième trimestre
05/13La perte nette d'Instil Bio au premier trimestre se creuse ; les dépenses augmentent
04/27Instil Bio reçoit la désignation de médicament orphelin de la FDA pour ITIL-168 dans le..
More news
Analyst Recommendations on INSTIL BIO, INC.
More recommendations
Chart INSTIL BIO, INC.
Duration : Period :
Instil Bio, Inc. Technical Analysis Chart | TIL | US45783C1018 | MarketScreener
Technical analysis trends INSTIL BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 19,81 $
Average target price 30,00 $
Spread / Average Target 51,4%
EPS Revisions
Managers and Directors
Bronson Crouch Chairman & Chief Executive Officer
Sandeep Laumas Chief Financial & Business Officer
Zachary Roberts Chief Medical Officer
Vijay Chiruvolu Chief Technical Officer
George Matcham Director
Sector and Competitors
1st jan.Capi. (M$)
INSTIL BIO, INC.0.00%2 554
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888